• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to heterocyclic compounds, in particular to the preparation of the imidazole derivatives of the NYN-N-CH-C Rs h-C h -Ve v-cm 3 it -CH-, H 3s h. Where R and RC each are lower alkyl, RyH and or RJ + 4 is an additional link between C and N, Rg-- H, lower: alkyl or alkylthio, or their pharmaceutically acceptable salts with acids, which can be used to treat and prevent inflammation and edema. The goal is to develop a method of producing compounds with activity that is not characteristic of this range of compounds. The preparation is carried out by condensation of the compound f-ly (NH (2), where Rs is indicated above, with the corresponding aldehyde. The resulting compound is isolated or reduced. In the case of a lower alkylthio group, the process is carried out with the cleavage of the lower.; the desired products in free form or in the form of a pharmaceutically acceptable salt. 2 tab.
    公开号:SU1657057A3
    申请号:SU884355836
    申请日:1988-03-18
    公开日:1991-06-15
    发明作者:Клетцер Вильхельм；Монтавон Марк；Мюсснер Ренате；Сингевальд Николас
    申请人:Ф.Хоффманн-Ля Рош Унд Ко.Аг, (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a process for the preparation of new imidazole derivatives or their pharmaceutically acceptable salts, which can be used for the treatment and prevention of inflammation and edema.
    The purpose of the invention is the synthesis of new compounds in the range of imidazoles, which have activity that is not characteristic of this range of compounds.
    Example 1. a. 5 g of hydroxyl-amine-0-sulfonic acid is dissolved in
    30 ml of water and neutralize 3.7 g of sodium bicarbonate with ice cooling. This solution is then added dropwise to a solution of 3.63 g of 2-methyl-imidazole in 15 ml of water. The resulting mixture is stirred for about 20 hours at room temperature and acidified with 13 ml of 2N. hydrochloric acid until the solution reaches a pH of 1. Then add two portions of active carbon (with a spatula tip), mix for 15 minutes,
    ABOUT
    was eating VI was eating VI

    with
    filter and add L ml of benzaldehyde and 10 ml of diethyl ether to the resulting clear filtrate. Then it is stirred for 6 hours, cooled for 15 minutes in an ice bath and the precipitated solid is filtered. The filtrate is further processed as described below.
    After re-precipitating the solid from a mixture of methanol and diethyl ether, 1,3-bis (benzylideneamino) -2 -2 methylimideolyl chloride, m.p. square 244-249 ° C.
    The resulting filtrate is extracted three times with shaking with diethyl ether (15 ml each). The aqueous phase with cooling is neutralized (pH 7) 9 ml 4 n. caustic soda solution. Then, the resulting precipitate is filtered off, re-precipitating it from a mixture of methanol and dc tyl ether, resulting in 1-benzylidene-anino 2-methylimidazole, m.p. 122- 124 ° C.
    B.3.24 g. 1,3-bis (benzylidene no) -2-methylimidazolium chloride is dissolved in 50 ml of methanol. The resulting solution is cooled to an internal temperature of 0 ° C, after which a solution of 2.5 g of potassium cyanide in 8 ml of water is added with stirring. At the same time, the temperature should not increase significantly. After 15 minutes, methanol is evaporated.
    at the minimum temperature in vacuum. The resulting residue was diluted with 30 ml of water, followed by extraction with chloroform. The dried chloroform extract is evaporated, whereby 1-benzylidene-amino-2-methylimidazole is obtained with m.p. 12bc
    C. 7.4 g of 1-benzylideneamino-2-methylimndazole is weighed into 50 ml of water. The slurry is acidified (to a pH of 1-2) with 25 ml of 2N hydrochloric acid, after which it is subjected to steam distillation until the benzaldehyde is distilled. The remaining clear solution is evaporated to dryness, and the oily residue is recrystallized at 0% C using diethyl (.
    the ether. The crystals obtained are reprecipitated from a mixture of ethanol and danethyl ether, i, which gives 1-amino-2-methylimidazole hydrochloride with m.p. 139-K1 S.
    5,35 g of 1-amino-2-methylimidazole-β-hydrochloride is dissolved in 300 ml.
    ethanol, then 9.3 g are added

    d
    $
    five
    0
    five
    4-hydroxy-3.5-di-tert-butylbenzaldehyde and stirred for 1 hour at room temperature. The mass is then evaporated in vacuo. 150 ml of ice water and 200 ml of methyl chloride are added to the residue, stirred and neutralized (pH 7) with a saturated solution of sodium bicarbonate. The methylene chloride phase is then separated, and the aqueous phase is extracted with 100 ml of methylene chloride. The collected methylene chloride phases are dried and evaporated. The residue is stirred in diethyl ether, filtered, and the filtrate is dried in vacuo at 80 ° C. The result is 1- - (4-hydroxy-3,5-di-tert-butylbenzylidene-amino) -2-methylimidazole, m.p. 206-207 HP.
    Example 2. 3.13 g of 1- (4-hydroxy-3,5-di-tert-butylbenzylideneamino) -2methylimidazole is dissolved in 100 ml of methanol, after which 0.5 g of palladium catalyst (5% on carbon) is added and 10 ml of 1 n. hydrochloric acid and hydrogenated under normal pressure and at room temperature. After uptake of 240 ml of hydrogen, the catalyst is filtered off and the filtrate is evaporated. The oily residue is dissolved in 50 ml of water and a saturated solution of sodium bicarbonate is added until neutrality (pH 7) is achieved. The precipitate formed is filtered off and added to 100 ml of methylene chloride. The methylene chloride solution is washed with 50 ml of water, dried and evaporated. The residue is stirred in diethyl ether, filtered and the crude 1- (4-hydroxy-3,5-di-tre t-butylbe ns yl-amino) -2-methylimidazole is obtained with mp. 181-. By recrystallization from acetonitrile, a pure product was obtained with mp. 182-183 ° C.
    Example 3. a. 22.6 g of hydroxylamine-0-sulfonic acid are dissolved in 60 ml of ice-cold water and neutralized (to pH 6) approximately 18 g of sodium bicarbonate. Then a solution of 27.2 g of imidazole in 60 ml is added dropwise with stirring for 45 minutes.
    water. The resulting mixture is then stirred for about 20 hours at a lump, at a natural temperature and acidified with 2N. hydrochloric acid (ft-160 ml) with ice cooling to pH 1-2. Then dark solution is stirred for 15 minutes with activated carbon, filtered
    and 28 ml of benzaldehyde and 30 ml of diethyl ether are added to the resulting clear filtrate. The mass is then stirred for 18 hours, cooled, the resulting slurry is formed for 15 minutes, and the precipitated 1,3-bis (benzylideneamino) imidazone chloride is filtered.
    The filtrate is extracted three times by shaking with diethyl ether (AO ml). Then they neutralize (to pH 7) the aqueous acid phase, cooling it with ice, 40 ml 4 n. caustic soda solution. The precipitate is extracted once by shaking 100 ml of chlorosorma and twice more with chloroform (20 ml each time). The collected chloroform phases are dried with sodium sulfate and evaporated. The resulting residue is dissolved in ethanol with heating, after which an amount of hot water is added so that no turbidity is observed. Then quickly filtered and cooled. After cooling with ice for 1 h, the precipitated 1-benzylideneaminoimide-eol is filtered off.
    b. Similarly to the method described in Example 16, from 1, 3-bis- (benzylideneamino) imidase oliychloride, 1-benzylideneaminoimidazole is obtained with m. pl. 115 ° C
    C. 8.68 g of 1-benzylideneaminoimidazole is weighed into 50 ml of water. The resulting suspension is acidified (pH 1-2) 28 ml
    2 n. solution of hydrochloric acid and subjected to its distillation with water vapor to stop the distillation of benzaldehyde. The remaining clear solution in vacuo at 50-bOeC is evaporated to dryness. The evaporation residue crystallizes out in diethyl ether. By re-precipitating the crystallized mixture from a mixture of ethanol and diethyl ether, 1-amino-imidazole-hydrochloride is obtained with a mp. .
    0.48 g of 1-amino-imidazole hydrochloride is weighed into 30 ml of ethanol, after which 0.93 g of 4-hydroxy-3,5-di-tert-butyl-benzaldehyde is added. The suspension is stirred for 3 hours at room temperature.
    temperature This forms a clear solution, which is evaporated in vacuo. The residue is dissolved in 15 ml of water, neutralized (pH 7) by the addition of an ice-saturated saturated solution of sodium bicarbonate and quickly shaken with methylene chloride.
    (30 ml each). The collected organic (dried several times with sodium sulfate, filtered and evaporated in vacuo. Sublimation of the residue (Torr) gives 1- (4-hydroxy-3,5-di-tert-butylbenzylideneamino) imidazole with mp 171-174 C.
    Example 4. 0.9 g of 1- (4-hydroxy-3, 5-di-tert-butylbenzylideneamino)
    imidazole is weighed in 10 ml of ice. acetic acid. To the slurry is added 1, L. g of sodium cyanoborohydride, as a result of which a solution is formed,
    5 which is stirred overnight, after which it is evaporated under vacuum. 10 ml of water are added to the residue, neutralized (pH 7) by adding an ice-saturated saturated solution of sodium bicarbonate and shaken three times with methylene chloride (30 ml each time). The collected organic phases are dried with sodium sulfate, filtered and evaporated in vacuo. The residue is crystallized
    5 in diethyl ether. The product is filtered off and reprecipitated from a mixture of ethanol and water, the result is 1- (4-hydroxy-3,5-di-tert-butylbenzyl-ylamino) imidazole with m.p. 171-174 C.
    Example 5 28.7 g of 1- (4-hydroxy-3,5-di-tert-butylbenzylideneamino) imidazole are dissolved in 50 ml of methanol, after which 96 ml of 1N is added. hydrochloric acid and 3 g of Pd / C are hydrogenated under normal pressure and at room temperature. After uptake of 2.2 liters of hydrogen, the catalyst is filtered off and the filtrate is evaporated. 800 ml of methylene chloride and 300 ml of shaking water are neutralized (to pH 7) with a saturated solution of sodium bicarbonate, the methylene chloride phase is separated and the aqueous phase is extracted twice with methylene chloride.
    (100 ml). The methylene chloride phases are then collected, dried and evaporated, after which the resulting residue is recrystallized from the mixture.
    0 ethanol and water (3: 1). The result is 1- (4-hydroxy-3,5-di-tert-butylbenzylamino) -imidazole c. m.p. 178-180sS.
    Example 6. a. Solution 120 ml
    e of carbon disulfide and 60.6 g of dicyclohexyl-carbodiimide in 300 ml of THF are cooled down with a mixture of ice and salt. Then 39.9 g of aminoacetaldehyde are added dropwise with stirring.
    diethyl acetal at such a rate that the temperatures 4 of the reaction mass did not rise above (approximately 1 h). Then the mixture is slowly heated to room temperature (approximately 2 hours) by stirring and allowed to stand overnight. The resulting precipitate (dicyclohexyl thiourea) is filtered off and washed intensively with n-hexane. The filtrate is concentrated in vacuo, and the precipitated dicyclohexyl urea is filtered again and intensively washed with n-hexane. This procedure is repeated until the dicyclohexylthiourea precipitation ceases upon concentration. Finally, the solvent is completely removed from the filtrate. The residue was distilled at 11 Torr (bath temperature 130-134 °), resulting in 2.2-diethoxyethyl isothiocyanate in the form of a colorless oil with mp. 100 ° C / 11 Torr.
    B.2.5 g of hydrazine hydrate (98-100%) is dissolved in 10 ml of 96% ethanol. 8.75 g of 2,2-diethoxyethyl isothiocyanate are added dropwise to this solution with stirring at such a rate that the temperature of the solution does not exceed. When the addition is complete, cool the contents of the flask, which then completely solidifies. Ethanol is evaporated in vacuo at a bath temperature of 30–40 ° C. The remaining 4- (2.2-dielectric, Si-ethyl) thiosemicarbazide as a colorless crystalline residue (mp. 92–97 ° C) is not suitable for further processing without purification. The sample, recrystallized from water, has so pl. 95-97 С
    In. To 2.07 g of 4- (2g, 2-diethoxyethyl) thiosemicarbazda, add 10 ml of 2N. sulfuric acid and the mixture is heated for 15 minutes at reflux temperature in a bath of boiling water. Then 1.06 g of benzaldehyde is added to the yellowish solution and everything is well stirred. After cooling to room temperature, the yellow precipitate is filtered off and washed with water and dried. In order to purify, the crude product is weighed in hot water (15 ml) and in the hot state as much ethanol is added to the slurry as needed. the completely dissolved substance. This solution is filtered in a hot state, after which it
    657078
    cool. This results in 1-benzylidene-amino-2-mercaptoimidazole in the form of white needles. Sample of this product
    0
    five
    0
    five
    Q
    dried for 12 hours at 40 ° C with a pressure of 10 Torr and it detects m. pl. 158-161 ° C.
    10.106 g of 1-benzylideneamino-2- -mercaptoimidazole is weighed in 30 ml of absolute ethanol, after which a solution of 1.15 g of sodium in 70 ml of absolute ethanol is added to the resulting suspension. Then, 7.1 g of methyl iodide is added and the reaction mixture is stirred for 3 hours at room temperature. Then the resulting yellow solution is concentrated to a quarter of the volume and topped up with 100 ml of water. The resulting crystalline crude product is filtered off, washed three times with water and recrystallized from a mixture of methanol and water. The result is 1-benzylidene-2- -mercaptoimidazole with so pl. 95-97 C.
    2, 17 g of 1-benzylideneamino-2-mercaptoimidazole is weighed into 50 ml of water and after adding 6 ml of 2N. hydrochloric acid, the mixture obtained is subjected to steam distillation. At the end of benzaldehyde cleavage, the resulting solution is concentrated to a volume of a few milliliters, after which 5N is added until the alkaline reaction is reached. sodium hydroxide solution and extracted five times with methylene chloride (15 ml). Then the collected methylene chloride phases are dried with sodium sulfate, filtered and evaporated. The crystalline residue is then recrystallized from a mixture of n-hexane and ethyl acetate. The result is 1-amino-2-methyl-mercaptoimidazole in the form of colorless crystals with mp. 71-73 C (sublimation begins with temperature).
    e. 0.65 g of 1-amino-2-methylmercaptoimidazole is dissolved in 50 ml of methanol, after which 3 ml of 2N is added. hydrochloric acid. After adding 1.05 g of 4-hydroxy-3,5-di-tert-butylbenzaldehyde, the reaction mixture is stirred overnight at room temperature. The solvent is then evaporated in vacuo, the residue is weighed in 30 ml of water and a saturated solution of sodium carbonate is added until reaching an alkaline reaction. Then extracted three times with methylene chloride
    five
    0
    0
    (20 ml each), the collected organic phases are dried with sodium sulfate, filtered and evaporated. The resulting crystalline residue is recrystallized from a mixture of water and methanol. The result is 1- (4-hydroxy-3, 5- -di-tert-butylbenzylideneamino) -2- -methylmercaptoimidazole with m. Pl. 181-.
    EXAMPLE 7 1.04 g of 1- (4-hydroxy-3,5-di-tert-butylbenzylideneamino-2-methyl mercaptoimidazole is dissolved in 20 ml of glacial acetic acid. 0 is added in portions to the solution in 30 minutes , 43 g of 90% sodium cyanoborohydride. The reaction mass is stirred overnight at room temperature. Then the solvent is evaporated in a vacuum, the residue is taken up in 20 ml of water. A saturated solution of sodium carbonate is then added until it is alkaline and extracted three times with methylene chloride (15 ml each). The collected organic phases are dried with sodium sulfate , filtered and evaporated. The residue is recrystallized from a mixture of methanol and water, resulting in a yield of 1- (4-hydroxy-3, 5-di-tert-butyl-benzyl-amino) -2-methyl mercaptoimidazole with mp 110 -113 S.
    Example 8. Option a. 200 mg of 1- (4-hydroxy-3, 5-di-tert-butylbenzyl-amino) -2-methyl mercaptoimidazole together with 0.41 g of nickel (II) chloride. 6 g is dissolved in 8 ml of methanol. The resulting solution was cooled in an ice bath and 0.7 g of sodium borohydride was added in portions over 1 hour. When the addition is complete, remove the ice bath and stir the black reaction mixture for another 4 hours at room temperature. For further processing, the mass is cooled again and 2 n. hydrochloric acid to the acid reaction of the reaction mass. Then it is stirred for a few more minutes and concentrated ammonia is added until it is alkaline. The mass is then filtered through a layer of silica gel and the cake is washed 5 times with methylene chloride. The organic phase of the filtrate is then separated, washed twice with water, dried with sodium sulfate and evaporated. The crystalline residue is reprecipitated with a mixture of methanol and water. Get 1- (4-hydroxy-3,5-di-tert-butylbenzylamino) imidazole in

    0
    five
    Q
    as colorless crystals of st. square 171-174 ° C .- /
    Option b. 600 mg of 1- (4-hydroxy-3,5-β-di-tert-butylbenzylamino) -2-methyl-mercaptoimndazole dissolved in 20 ml of ethanol, together with Nickel-wetted W2 Wan in ethanopium in excess of the amount of imidazole by weight 5 times, with stirring for two hours, heated to 60-70CC. Then nickel is filtered off and washed twice with ethanol (10 ml each). The collected alcohol filtrates are evaporated. As a residue, 1- (4-hydroxy-3,5-di-tert-butylbenzylamino) -imidazole is obtained in the form of colorless crystals with m.p. 171-174 ° C.
    Example 9. 300 mg of 1- (4-hydroxy-3,5-di-tert-butylbenzylamino) imidazole together with 10 drops of glacial acetic acid in 25 ml of benzene in a water bath are heated to a temperature of 5 l / 60 -70 ° C. After adding dropwise a solution of 250 mg of dicyanodichlorobenzoquinone in 10 ml of benzene, the resulting reaction mass is heated for another 15 minutes. It is then cooled in an ice bath 0 and the precipitated solid is filtered. The filtrate is then shaken with a 10% sodium carbonate solution. After separation of the organic phase, the aqueous phase is extracted once with benzene. The collected organic phases are dried with anhydrous magnesium sulphate, filtered and evaporated under reduced pressure. The crystalline residue is then recrystallized from a mixture of ethyl acetate and n-hexane, whereby 1- (4-y-oxy-3,5-di-tert-butylbenzylidene-amino) imidazole is obtained with m.p. 173.
    Example 10. a. 25 g of 2-propyl imidazole are weighed into 70 ml of water. Then, 25 g of hydroxylamino-0-sulfonic acid and 18.5 g of sodium bicarbonate in 150 ml of water are added to the suspension during 20 minutes with stirring. After stirring for 20 hours at room temperature, 65 ml of 2N are acidified. hydrochloric acid, a solution of 15.5 g of benzaldehyde in g of 50 ml of diethyl ether is added and the mixture is stirred for 6 hours at room temperature. The crystals formed are filtered. popping out. The filtrate is processed as described below.
    0
    five
    0
    The crystals are dissolved in methylene chloride. The solution is dried with sodium sulfate, filtered and concentrated. The residue is crystallized by the addition of diethyl ether. After recrystallization from ethanol, a 1,3-bis (benzylideneamino) -2-propyl-imidazolium-benzaldoxime-0 sud-fonate with m.p. 143-145CC.
    The filtrate is washed with diethyl ether. Then 60 ml of 3 n. sodium hydroxide solution and extracted with methylene chloride. After drying the extract with sodium sulfate, filtering and evaporating the methylene chloride, a reddish oil is obtained, from which chromatography on a gel-gel (grain size 0.063-0.2 mm) using a mixture of methylene chloride and methanol (99: 1%) gives 1-benzylidene- but-2-propyl imidazole with m. pl. 61-62 C.
    B. Suspension 14 g of 1-benzylideneamino -2-propyl imidazole in 113 ml of water and 79 ml of 2N. hydrochloric acid is subjected to steam distillation until benzaldehyde distillation is stopped. The remaining slightly confusing solution is cooled and evaporated in vacuo. Methanol and benzene are added to the oily residue, then the resulting mass is evaporated, after which 30 ml of ethanol are added. Diethyl ether is added to the resulting solution until the solution becomes cloudy. After cooling the solution, the precipitated crystals are filtered off, which are washed with diethyl ether and n-hexane and dried under vacuum at 60 °. Get 1-amino--2-propshmidazol hydrochloride with
    m.p. 108-109 ° C.
    B.6.47 g of 1-amino-2-propyl imidazole hydrochloride is dissolved in 300 ml of ethanol, after which 3.5 g of 4-hydroxy-3,5-di-tert-butylbenzaldehyde are added, stirred for 3 h at room temperature and then the resulting solution is evaporated. 150 ml of water and 150 ml of methylene chloride are added to the residue, after which a saturated solution of sodium bicarbonate is added with stirring until it reaches a neutral reaction (pH 7). The methylene chloride phase is separated and the aqueous phase is extracted once.
    50 ml of methylene chloride, after which the methylene chloride solutions are combined and dried and evaporated. Osta0
    five
    0
    five
    thirty
    55
    40
    45
    50
    five
    the current is mixed with diethyl ether with stirring, after which the solid is filtered off and dried at 60CC under vacuum. As a result, 1- (4-hydroxy-3,5-di tert-butylbenzylideneamino) -2-propyl imidazole with m. Pl. 160-161 ° C.
    Example 11. 9.9 g of 1- (4-hydroxy-3,5-di-tert-butylbenzylideneamino) -2-propylimidazole are hydrogenated in 200 ml of methanol and 29 ml of 1N. hydrochloric acid in the presence of 1 g of palladium catalyst (5% on coal) under normal pressure at room temperature. When 700 ml of hydrogen is absorbed, the catalyst is filtered off and the filtrate is evaporated. The residue is dissolved in 100 ml of water, after which a saturated solution of sodium bicarbonate is added until neutrality (pH 7) is reached. The precipitated crystals are then filtered off and dissolved in 300 ml of methylene chloride. The methylene chloride solution is washed once with water, dried and evaporated. The residue is dissolved in 50 ml of hot isopropyl ether. The crystals precipitated during cooling are filtered off, washed with isopropyl ether and n-hexane and dried at 60 ° C under vacuum. The result is 1- (4-hydroxy-3,5-di-tert-butylbenzylamino) -2-propyl-imidazole with m.p. 122-123dC.
    Imidazole derivatives of the general formula (1) and their pharmaceutically acceptable salts with acids possess valuable pharmacodynamic properties.
    In the animal experiment described, the anti-inflammatory properties of representative compounds of formula (1) were tested.
    Male rats (120-140 g) were injected into the root of the tail with 0.1 ml of a 0.5% (w / v) suspension of the heat-killed and dried microbacterium Mycobacterium butyricum in a heavy mineral oil containing 0.2% digitonin. Animals are kept separately, fed by and under t. The arthritis caused in this way is allowed to develop for 21 days, after which the weight of the animals is determined, on the one hand, and the volume of both hind paws (by immersing the paws in a mercury plethysmograph to the level of the ankle lateral), on the other. The animals are then grouped into groups of 6 individuals, whose hind legs have approximately the same average volume and, during 7 days, they inject the test substance by intubation. At the end of the treatment cycle, body weight and hind paw volume are again determined and their change during treatment is counted. Animals are then killed, plasma samples are taken and the amount of fibrinogen is determined by the method of Exner (Amer. J. Cl in Path), precipitated by ammonium sulfate.
    In the following table. 1 shows the results obtained in the described experiment with three represented compounds of the indicated formula (vl).
    Below are data on the acute toxicity of the above three compounds (DCSO, with a single oral administration in mice). ABC Compound
    Ldda, mg / kg, (oral)
    1000 1000
    - In addition, in the experiment on animals, the edema inhibiting effect of the indicated compound A and compounds B-1- (4-hydroxy-3,5-di-tert-butylbenzylamino) -2-methyl-imidazole and E-1- ( 4-hydroxy-3,5-di-tert -butylbenzylamino) -2-propyl imidazole, which formula (I) also covers. In male rats (230-250 g), which receive food and water, as long as they please, by injecting 0.2 ml of a 1% solution of carrageen (Carrageen) in sterile non-alcoholic solution of common salt into the right pleural cavity cause pleurisy. 1 hour before the injection of carrageen and 5 hours after that, the substances tested in an aqueous carrier (containing 0.5% carboxymethylcellulose, 0.9% sodium chloride, 0.37% Tween 80 and 0.86% benzyl alcohol), and the carrier, respectively. 24 hours after the injection of carrageen, animals are killed, beheaded, released
    All the blood from the animal carcass is opened and the pleural cavity is opened, the ribs are divided on both sides of the sternum. Exudate is removed from the pleural cavity with a pipette and its volume is determined. The pleural cavity is then washed once with a solution of sodium chloride containing phosphate as a buffer and fetal bovine serum (1: 1) and
    - Q
    five
    0
    five
    0 Q
    combine the wash solution with the exudate. Using the Coulter Counter, which is adjusted so that red blood cells are not counted, the total number of cells in the pleural cavity is calculated. Cell smears on glass plates can be obtained directly from the exudate. They are fixed with methanol and stained for differential counting of polymorphonuclear leukocytes (PML) and macrophages: a total of 200 PML and macrophages are counted. The result can be expressed as a percentage for each cell type present in the pleural exudate.
    The results of the described experiment are given in table. 2
    The compounds of formula (I) and their pharmaceutically acceptable salts with acids find use as therapeutic agents, for example, in the form of pharmaceutical preparations. Pharmaceutical preparations can be administered orally, for example, in the form of tablets, including those with a lacquer coating, dragees, soft or hard gelatin capsules, solutions, emulsions or suspensions. However, the administration of these preparations can also be carried out rectally, for example, in the form of suppositories or parenterally in the form of injection solutions.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of obtaining imilazole derivatives of General formula (I)
    Ness / RI
    J-n-ch
    N-yN
    "5 R4 R3
     where K. and K. are each lower alkyl;
     hydrogen and Hc are hydrogen or R — J and R c. together mean an additional bond between carbon and nitrogen; RC- - hydrogen, lower alkyl
    or lower alkylthio
    or their pharmaceutically acceptable salts with acids, characterized in that the compound of General formula (II)
    g
    R5 nh
    where Kd, Rs have the indicated values,
    are isolated or reduced to form compounds of the general formula (U
    where Rg has the indicated meanings, it is condensed with an aldehyde of general formula (III)
    CH,
    where RJ and R have the indicated meanings, and the resulting compound of the general formula (1a)
    NYN-M - CH Rs
    CH3
    The value differs significantly from the corresponding value obtained in animals that were injected only with vehicle (p.0.05; Students t-Test), while A - 1- (4-hydroxy-3,5-di-tert-butylbenzylamino) imidazole , B - 1- (4-hydroxy-3,5-di-tert-butylbenzylideneamino) -2-methylimidazole, C - 1- (4-hydroxy-3,5-di-tert-butylbenzylideneamino) imidazole.
    il -M-Ub b5
    WITH
    / v
    SI # 2
    where Rj, R4 and R6 are as defined,
    with the endowment of the desired product or, in the case where the R $ -, lower alkylthio group with the cleavage of the lower alkylthio group or the compound of general formula (1c) is dehydrated and the desired products are isolated in free form or as a pharmaceutically acceptable salt.
    Table 1
    17
    L
    The value differs significantly from the corresponding value obtained in animals injected with only the vehicle (p 0.05, Students t-Test).
    165705718
    table 2
    类似技术:
    公开号 | 公开日 | 专利标题
    US4048306A|1977-09-13|Aldehyde-erythromycylamine condensation products
    SU1657057A3|1991-06-15|Method for obtaining imidazole derivatives of their pharmaceutically suitable salts with acids
    NL7907914A|1980-05-06|NEW 4- | ALKYL-2-IMIDAZOLIDINONE DERIVATIVES AND METHOD FOR THE PREPARATION THEREOF.
    DE1795699C3|1975-12-18|
    EP0218027B1|1989-09-20|Novel guanidinomethylbenzoic acid derivatives
    US3868457A|1975-02-25|Method of inhibiting histamine activity with guanidine compounds
    US3968216A|1976-07-06|Method of inhibiting histamine activity with guanidine compounds
    EP0165422B1|1988-03-09|Substituted bis-|-sulphones, their preparation and their use as medicines
    RU1797610C|1993-02-23|Process for preparing | guanidines or pharmaceutically acceptable salts thereof
    US4196292A|1980-04-01|6-Substituted amiloride derivatives
    US4939164A|1990-07-03|Strontium salt
    US4058597A|1977-11-15|Aluminium salts of betaine chloride and compositions containing the same
    US3652579A|1972-03-28|1-methyl-2-substituted 5-nitroimidazoles
    FI62089B|1982-07-30|FREQUENCY REQUIREMENT FOR THE PERFORMANCE OF PERIPHERAL BLODOMLOPPET NETWORK 7- | -N-AMINO) -1,3-DIALKYL-XANTINDERIVAT
    US3393201A|1968-07-16|1-methyl or 2-hydroxy ethyl-2-carbamyl-5 nitropyrroles
    EP0304534A1|1989-03-01|Dihydropyridazinone derivatives, method for their preparation and medicines containing the compounds
    CA1171421A|1984-07-24|Lysine salts having analgesic activity
    US4212874A|1980-07-15|Glyoxal-2-oxim derivatives and a process for relieving pain/or inflammation therewith
    BE779775A|1972-08-24|DERIVATIVES OF UREA, METHOD FOR PREPARING THEM AND THEIR APPLICATIONS
    SK278141B6|1996-02-07|Enolether amide 1,1-dioxo-6-chloro-4-hydroxy-2-methyl-n- -|-2h-thieno|1,2-thiazine-3-carboxylic acid, method of its production and pharmaceutical agent
    EP0000452A1|1979-01-24|1,2,4-Oxadiazol derivatives, their preparation and application in pharmaceutical compositions
    US4088769A|1978-05-09|Method of inhibiting histamine activity with guanidine compounds
    DE1445606A1|1969-01-23|Benzoazacycloalkenes
    SU1080744A3|1984-03-15|Process for preparing derivatives of benzodiazepine
    US4048319A|1977-09-13|Method of inhibiting histamine activity with quanidine compounds
    同族专利:
    公开号 | 公开日
    FI880813A0|1988-02-22|
    AU613349B2|1991-08-01|
    HUT49581A|1989-10-30|
    EP0283857B1|1992-03-18|
    IL85725A|1991-12-12|
    YU46444B|1993-10-20|
    YU40388A|1990-02-28|
    MC1919A1|1989-04-06|
    AU1353288A|1988-09-22|
    AT73777T|1992-04-15|
    GR3004729T3|1993-04-28|
    NZ223862A|1990-08-28|
    MX10721A|1993-09-01|
    ZA881810B|1988-09-20|
    IL85725D0|1988-08-31|
    US4908363A|1990-03-13|
    NO170215C|1992-09-23|
    HU201312B|1990-10-28|
    ES2032482T3|1993-02-16|
    CS276093B6|1992-04-15|
    KR880011117A|1988-10-26|
    JPS63253070A|1988-10-20|
    DK59888A|1988-09-21|
    PT87025B|1992-06-30|
    EP0283857A1|1988-09-28|
    PT87025A|1988-04-01|
    CS8800891A2|1990-09-12|
    DE3869163D1|1992-04-23|
    CN88101452A|1988-10-05|
    FI880813A|1988-09-21|
    NO170215B|1992-06-15|
    NO881199D0|1988-03-18|
    CN1016169B|1992-04-08|
    NO881199L|1988-09-21|
    DK59888D0|1988-02-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4457859A|1980-07-31|1984-07-03|Ivaschenko Alexandr V|Mesomorphic material containing 2,2'-azoimidazole compounds containing 1,1'-benzylideneamino substituents|
    EP0200947B1|1985-04-26|1990-09-12|F. Hoffmann-La Roche Ag|1,3-disubstituted imidazolium salts|
    ZW6687A1|1986-05-13|1987-12-02|Hoffmann La Roche|1,3-disubstituted imidazolium salts|
    MW7087A1|1986-10-03|1988-05-11|Hoffmann La Roche|1,3-disubstituted imidazolium salts|
    EP0283245A1|1987-03-20|1988-09-21|E.I. Du Pont De Nemours And Company|Fungicidal aminotriazoles and aminoimidazoles|US5073566A|1989-11-30|1991-12-17|Eli Lilly And Company|Angiotensin ii antagonist 1,3-imidazoles and use thereas|
    US5401851A|1992-06-03|1995-03-28|Eli Lilly And Company|Angiotensin II antagonists|
    US5612360A|1992-06-03|1997-03-18|Eli Lilly And Company|Angiotensin II antagonists|
    US5574057A|1993-02-03|1996-11-12|University Of Utah Research Foundation|Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent|
    US5523310A|1994-12-05|1996-06-04|Hoffmann-La Roche Inc.|1,2,3-triazole derivatives|
    WO2000031052A1|1998-11-23|2000-06-02|F. Hoffmann-La Roche Ag|Synthesis of anti-inflammatory [1,2,3]triazoles|
    DE10132896A1|2001-07-06|2003-01-16|Bayer Cropscience Ag|Heterocyclic amide derivatives|
    WO2003010143A1|2001-07-26|2003-02-06|Samsung Electronics Co., Ltd.|Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses|
    EP1431292A1|2002-12-16|2004-06-23|Laboratoire Theramex|1-N-phenylamino-1H-imidazole derivatives as aromatase inhibitors|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    CH107387|1987-03-20|
    [返回顶部]